A comprehensive analysis of advanced kidney cancer tumors from the IMmotion151 trial provided new insights on the tumor features that underpin responses to therapy.
If the current COVID-19 trends persist, the NCI estimates that the pandemic’s impact could threaten the trend of annually decreasing cancer mortality seen in the US since 1990.
Despite relying on glycolysis, there is growing evidence that many tumor types still have high levels of mitochondrial energy metabolism and functioning oxidative phosphorylation. One such subset of tumors is melanoma, potentially playing a role in both tumor progression and resistance to therapy. This has led researchers to wonder whether targeting mitochondrial respiration could be…
In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
Telemedicine has become more crucial than ever in the continuing wake of the COVID-19 pandemic. Research from the US Centers for Disease Control and Prevention (CDC) showed that there was a 50% increase utilization of telehealth services in the first quarter of 2020 compared with 2019, and a 154% increase in week 13 of 2020…
How effective is surgical treatment for ductal carcinoma in situ (DCIS) at preventing an invasive recurrence of breast cancer? Treatment is intended to significantly lessen the lifetime risk of breast cancer and breast cancer-related mortality, but are patients diagnosed with DCIS still at risk for experiencing poor outcomes? A recent study in JAMA Network Open…
Preferences are tied not just to the experience of receiving an injection, but also to factors related to a patient’s access to different types of care settings.
Phase 3 clinical trial of paclitaxel and atezolizumab shows no significant survival benefit, but questions remain over FDA decision to issue safety alert.
